{
  "trial_id": "NCT01624493",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histologically or cytologically proven diagnosis of epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer, including all histological subtypes and carcinosarcoma.",
      "label": "met"
    },
    {
      "criterion": "Progression-free interval between 4 to 9 months after first line chemotherapy or 4 to 12 months after second-line chemotherapy with a platinum (cisplatin or carboplatin) based regimen.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Non-epithelial ovarian cancer and ovarian tumours of low malignant potential (borderline tumours).",
      "label": "triggers"
    },
    {
      "criterion": "More than two prior chemotherapy regimens for ovarian cancer (excluding hormonal therapy or biologic agents).",
      "label": "triggers"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "39",
    "trial_id": "NCT01624493",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}